Cover Image
市場調查報告書

胃炎:開發中產品分析

Gastritis - Pipeline Review, H1 2018

出版商 Global Markets Direct 商品編碼 360905
出版日期 內容資訊 英文 53 Pages
訂單完成後即時交付
價格
Back to Top
胃炎:開發中產品分析 Gastritis - Pipeline Review, H1 2018
出版日期: 2018年05月08日 內容資訊: 英文 53 Pages
簡介

本報告提供胃炎治療藥的開發情形相關調查分析,開發中產品的概要,治療藥的開發合作的主要企業及藥物簡介,最新的開發平台趨勢等資訊。

簡介

  • 調查範圍

胃炎概要

治療藥的開發

  • 開發中產品的概要
  • 各企業的開發平台
  • 企業開發中的產品

治療藥的評估

  • 各標的
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • BCWorld Pharm Co Ltd
  • Boryung Pharmaceutical Co Ltd
  • Daewon Pharm Co Ltd
  • Recce Ltd
  • RedHill Biopharma Ltd

藥物簡介

胃炎:暫停中的計劃

胃炎:產品開發里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC10404IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gastritis - Pipeline Review, H1 2018, provides an overview of the Gastritis (Gastrointestinal) pipeline landscape.

Gastritis is characterized by inflammation or swelling of the lining of the stomach. Acute gastritis lasts for a short period of time while chronic gastritis lasts for a long period of time (months to years). Gastritis can be caused by medications such as ibuprofen, aspirin, naproxen on long periods of consumption, excess intake of alcohol, Helicobacter pylori infection, certain autoimmune disorders, bile reflux, substance abuse (cocaine), consumption of corrosive or caustic substances such as poisons, extreme stress, viral infections and trauma. The symptoms of gastritis may include loss of appetite, nausea and vomiting, abdominal pain and black stools. Treatment includes use of antacids, Histamine 2 (H2) antagonists and proton pump inhibitors.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Gastritis - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Gastritis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Gastritis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Gastritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 4, 2 and 2 respectively.

Gastritis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Gastritis (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Gastritis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Gastritis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Gastritis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Gastritis (Gastrointestinal)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Gastritis (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Gastritis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents 2
  • List of Tables 4
  • List of Figures 4
  • Introduction 5
  • Global Markets Direct Report Coverage 5
  • Gastritis - Overview 6
  • Gastritis - Therapeutics Development 7
  • Pipeline Overview 7
  • Pipeline by Companies 8
  • Products under Development by Companies 10
  • Gastritis - Therapeutics Assessment 11
  • Assessment by Target 11
  • Assessment by Mechanism of Action 13
  • Assessment by Route of Administration 15
  • Assessment by Molecule Type 17
  • Gastritis - Companies Involved in Therapeutics Development 19
  • BCWorld Pharm Co Ltd 19
  • Daewon Pharm Co Ltd 19
  • Daewoong Pharmaceutical Co Ltd 20
  • Recce Ltd 20
  • RedHill Biopharma Ltd 21
  • Sequella Inc 21
  • Gastritis - Drug Profiles 22
  • AK-002 - Drug Profile 22
  • Product Description 22
  • Mechanism Of Action 22
  • R&D Progress 22
  • BCWPA-001 - Drug Profile 24
  • Product Description 24
  • Mechanism Of Action 24
  • R&D Progress 24
  • DW-3101 - Drug Profile 25
  • Product Description 25
  • Mechanism Of Action 25
  • R&D Progress 25
  • DWJ-1366 - Drug Profile 26
  • Product Description 26
  • Mechanism Of Action 26
  • R&D Progress 26
  • HPi-1 - Drug Profile 27
  • Product Description 27
  • Mechanism Of Action 27
  • R&D Progress 27
  • netazepide - Drug Profile 28
  • Product Description 28
  • Mechanism Of Action 28
  • R&D Progress 28
  • ondansetron hydrochloride CR - Drug Profile 30
  • Product Description 30
  • Mechanism Of Action 30
  • R&D Progress 30
  • RECCE-327 - Drug Profile 39
  • Product Description 39
  • Mechanism Of Action 39
  • R&D Progress 39
  • SQ-109 - Drug Profile 42
  • Product Description 42
  • Mechanism Of Action 42
  • R&D Progress 42
  • Gastritis - Dormant Projects 46
  • Gastritis - Product Development Milestones 47
  • Featured News & Press Releases 47
  • Jun 19, 2017: RedHill Biopharma to Host Conference Call on Successful Phase III Top-Line Results with BEKINDA for Acute Gastroenteritis 47
  • Feb 13, 2017: RedHill Biopharma Announces Enrollment of Last Patient in BEKINDA Phase III Study for Acute Gastroenteritis 47
  • Nov 03, 2016: RedHill Biopharma Provides Update on Ongoing Phase III and Phase II studies with BEKINDA and Expected Timing of Top-Line Results 48
  • Mar 02, 2015: Positive Bioavailability Studies of RedHill's BEKINDA to be Presented at the 2015 American Society for Clinical Pharmacology and Therapeutics Meeting 49
  • Dec 17, 2014: RedHill Biopharma Announces First Patients Enrolled in the Phase III Study of RHB-102 (BEKINDA) for Gastroenteritis and Gastritis 50
  • Dec 09, 2014: RedHill Biopharma Submits BEKINDA (RHB-102) European Marketing Authorization Application for Oncology Support 51
  • Appendix 52
  • Methodology 52
  • Coverage 52
  • Secondary Research 52
  • Primary Research 52
  • Expert Panel Validation 52
  • Contact Us 52
  • Disclaimer 53

List of Tables

  • Number of Products under Development for Gastritis, H1 2018 7
  • Number of Products under Development by Companies, H1 2018 9
  • Products under Development by Companies, H1 2018 10
  • Number of Products by Stage and Target, H1 2018 12
  • Number of Products by Stage and Mechanism of Action, H1 2018 14
  • Number of Products by Stage and Route of Administration, H1 2018 16
  • Number of Products by Stage and Molecule Type, H1 2018 18
  • Gastritis - Pipeline by BCWorld Pharm Co Ltd, H1 2018 19
  • Gastritis - Pipeline by Daewon Pharm Co Ltd, H1 2018 20
  • Gastritis - Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2018 20
  • Gastritis - Pipeline by Recce Ltd, H1 2018 20
  • Gastritis - Pipeline by RedHill Biopharma Ltd, H1 2018 21
  • Gastritis - Pipeline by Sequella Inc, H1 2018 21
  • Gastritis - Dormant Projects, H1 2018 46

List of Figures

  • Number of Products under Development for Gastritis, H1 2018 7
  • Number of Products under Development by Companies, H1 2018 8
  • Number of Products by Targets, H1 2018 11
  • Number of Products by Stage and Targets, H1 2018 11
  • Number of Products by Mechanism of Actions, H1 2018 13
  • Number of Products by Stage and Mechanism of Actions, H1 2018 13
  • Number of Products by Routes of Administration, H1 2018 15
  • Number of Products by Stage and Routes of Administration, H1 2018 15
  • Number of Products by Molecule Types, H1 2018 17
  • Number of Products by Stage and Molecule Types, H1 2018 17
Back to Top